Get the Stockscreener App
2.62
3.68%
-0.10
Alterity Therapeutics Ltd Adr stock is traded at $2.62, with a volume of 55,910.
It is down -3.68% in the last 24 hours and down -31.95% over the past month.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
See More
Previous Close:
$2.72
Open:
$2.56
24h Volume:
55,910
Relative Volume:
1.60
Market Cap:
$47.71M
Revenue:
$-41,600
Net Income/Loss:
$-9.46M
P/E Ratio:
-0.0905
EPS:
-28.9457
Net Cash Flow:
$-8.70M
1W Performance:
-15.89%
1M Performance:
-31.95%
6M Performance:
-34.01%
1Y Performance:
-45.76%
1-Day Range:
$2.35
$2.955
1-Week Range:
$2.35
$3.40
52-Week Range:
$2.35
$5.8922
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Name
Alterity Therapeutics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare ATHE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
2.62 | 47.71M | -41,600 | -9.46M | -8.70M | -28.95 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-26 | Initiated | Craig Hallum | Buy |
| Jun-16-26 | Resumed | Ladenburg Thalmann | Buy |
| Feb-03-25 | Downgrade | The Benchmark Company | Speculative Buy → Hold |
| Dec-12-24 | Initiated | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr Stock (ATHE) Latest News
Immutep Limited (IMMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alterity Therapeutics (ATHE) ADR Edges Up 1.43% to $3.91, Holding Above $3.71 SupportAdvance Decline Line - https://www.dars.gov.et/
Alterity Therapeutics at Cantor healthcare conference: phase iii path sharpens By Investing.com - Investing.com South Africa
Alterity Therapeutics at Cantor healthcare conference: phase iii path sharpens - Investing.com
ALTERITY THERAPEUTICS LTD (NASDAQ: ATHE) Director Acquires 47,620 Shares at $0.50 Each - Kalkine Media
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Alterity Therapeutics Director David Stamler's Listed Options Expire on 31 August 2026 - Kalkine
Alterity Therapeutics Reports A$17.6M in R&D Expenses for Fiscal Year Ending June 30, 2026 - Kalkine Media
Alterity Therapeutics (ATHE) Holds Steady at $4.51 as Shares Consolidate Within a Tight Trading RangeATR Trailing Stop - careplusvn.com
Kazia Therapeutics LimitedADR Peer Comparison – Compare with Others - Value Research
Alterity (ATHE) Chart: Closes 4.94% Higher at $4.67; Technical View: the Near-Term Reference Band Stretches From $4.44 to $4.90 in the Latest SessionFibonacci Entry Signals - dars.gov.et
Alterity (ATHE) Chart: Closes 4.94% Higher at $4.67; Technical View: the Near-Term Reference Band Stretches From $4.44 to $4.90 in the Latest SessionDip Buy Trade - careplusvn.com
Alterity (ATHE): Advances 4.94% to $4.67 for the Current Session; Next Session: the Supplied Trading Band Runs From $4.44 to $4.90 in Latest TradingHigh Beta Stocks - dars.gov.et
Alterity (ATHE): Advances 4.94% to $4.67 for the Current Session; Next Session: the Supplied Trading Band Runs From $4.44 to $4.90 in Latest TradingNAAIM Leverage - dars.gov.et
Alterity Therapeutics (ATHE) Declines 4.6% to $4.57 as Shares Test Key SupportDelta Hedging - careplusvn.com
Alterity Therapeutics Limited (ASX:ATH) Share Price Falls 4.46% as Stock Trades Within Daily Range - Kalkine
Clinuvel Pharmaceuticals (ASX:CUV) Makes U.S. Pivot With Nasdaq Uplisting and Headquarters Shift Plan - Kalkine
Alterity Therapeutics Secures Key US Patent for Lead Asset - Sahm
Alterity Therapeutics at Canaccord conference: phase III path in focus By Investing.com - Investing.com India
Alterity Therapeutics at Canaccord conference: phase III path in focus - Investing.com
Craig-Hallum initiates Alterity Therapeutics stock coverage with buy rating - Investing.com
Acrux Ltd (ASX:ACR) Share Price Update: Trading Snapshot for 11 August 2026 - Kalkine
Alterity Therapeutics (ATHE) Climbs 3.41% as Shares Advance Toward $4.94 ResistanceLow Beta Factor - dars.gov.et
Alterity Therapeutics (ATHE) Climbs 3.41% as Shares Advance Toward $4.94 ResistancePut Dominated - careplusvn.com
Alterity Therapeutics (ATHE) Gains 1.24% to $4.5, Holding Above Key SupportFibonacci Fan - vinanet.vn
Alterity Therapeutics (ATHE) Gains 1.24% to $4.5, Holding Above Key SupportSentiment Divergence - dars.gov.et
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update - Yahoo Finance
PRNAF SEC FilingsALTERITY THERAPEUTICS LTD 10-K, 10-Q, 8-K Forms - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ATHE News | ALTERITY THERAPEUTICS-ADR (NASDAQ:ATHE) - ChartMill
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC FilingForm 6-K - Stock Titan
Jones Trading initiates Alterity Therapeutics stock with buy rating - Investing.com
Alteriry Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ATHE) - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Sahm
Insights: Alterity Therapeutics Ltd (ASX:ATHDA) - smallcaps.com.au
ATHEAlterity Therapeutics Ltd ADR Short Interest - Finviz
ATHEAlterity Therapeutics Ltd ADR Volatility & Greeks - Finviz
Weiss Ratings Stock Recommendations & Analyst Ratings 2026 - marketbeat.com
Alterity Therapeutics (NASDAQ: ATHE) sets vote on 50:1 consolidation and large option, incentive issuances - Stock Titan
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC FilingForm 6-K - Stock Titan
Alterity Therapeutics appoints Ann Cunningham to board - Investing.com
Alterity Therapeutics appoints Ann Cunningham to board By Investing.com - Investing.com India
Nerves settle as oil drops - The Cairns Post
Nerves settle as oil drops - Geelong Advertiser
Nerves settle as oil drops - Daily Telegraph Sydney
Alterity Therapeutics Receives Positive FDA Feedback for ATH434 Phase 3 MSA Program - smallcaps.com.au
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February - Defense World
Ameritas Investment Partners Inc. Raises Stock Holdings in Kratos Defense & Security Solutions, Inc. $KTOS - Defense World
Alterity Therapeutics Ltd Adr Stock (ATHE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):